secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001411690-25-000082
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Q2 2025 revenue $6.7M (-13% YoY); gross margin 52% vs 33%; flowcell sales +17%
--------------------------------------------------------------------------------

- Total revenue $6.7M (-13% YoY); prior year included $0.7M discontinued clinical services; adjusted consumables/software/services up 11%.
- Gross margin 52% (non-GAAP 52%) vs 33% a year ago; operating expenses cut 42% to $11.3M.
- Sold 7,233 flowcells (+17% YoY); installed OGM base 378 systems (+4% YoY).
- Full-year 2025 revenue reaffirmed $26-30M; Q3 2025 guidance $6.7-7.2M; cash runway into Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169025000082/0001411690-25-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169025000082/bngo-20250814.htm
  HTML page:      https://secwatch.observer/filing/0001411690-25-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer